XML 68 R17.htm IDEA: XBRL DOCUMENT
v2.4.1.9

SEGMENT INFORMATION | 12 Months Ended
--- | ---
Sep. 30, 2014
SEGMENT INFORMATION [Abstract] |
SEGMENT INFORMATION | 11. SEGMENT INFORMATION We operate in two principal segments – contract research services and research products. Our contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. We evaluate performance and allocate resources based on these segments. Certain of our assets are not directly attributable to the Services or Products segments. These assets are grouped into the Corporate segment and include cash and cash equivalents, deferred income taxes, refundable income taxes, debt issue costs and certain other assets. We do not allocate such items to the principal segments because they are not used to evaluate their financial position. The accounting policies of these segments are the same as those described in the summary of significant accounting policies.
| (a) | Operating Segments
|  | Years Ended September 30, |  |  |  |
|  | 2014 |  |  | 2013 |
Revenue: |  |  |  |  |  |  |  |
Service |  | $ | 19,097 |  |  | $ | 16,473 |
Product |  |  | 5,487 |  |  |  | 5,595 |
|  | $ | 24,584 |  |  | $ | 22,068 |
Operating income (loss) : |  |  |  |  |  |  |  |
Service |  | $ | 469 |  |  | $ | 77 |
Product |  |  | (135 | ) |  |  | 753 |
|  | $ | 334 |  |  | $ | 830 |
Interest Expense |  |  | (488 | ) |  |  | (649 | )
Change in fair value of warrant liability- (increase) decrease |  |  | (918 | ) |  |  | 601 |
Other income |  |  | 9 |  |  |  | 7 |
(Loss) income before income taxes |  | $ | (1,063 | ) |  | $ | 789 |
|  | Years Ended September 30, |  |  |  |  |
|  | 2014 |  |  | 2013 |  |  |  |  |
Identifiable assets: |  |  |  |  |  |  |  |
Service |  | $ | 14,132 |  |  | $ | 15,149 |
Product |  |  | 5,837 |  |  |  | 6,399 |
Corporate |  |  | 3,805 |  |  |  | 4,049 |
|  | $ | 23,774 |  |  | $ | 25,597 |
Goodwill, net: |  |  |  |  |  |  |  |
Service |  | $ | 1,009 |  |  | $ | 1,009 |
Product |  |  | — |  |  |  | 374 |
|  | $ | 1,009 |  |  | $ | 1,383 |
Depreciation and amortization: |  |  |  |  |  |  |  |
Service |  | $ | 1,421 |  |  | $ | 1,519 |
Product |  |  | 176 |  |  |  | 204 |
|  | $ | 1,597 |  |  | $ | 1,723 |
Capital Expenditures: |  |  |  |  |  |  |  |
Service |  | $ | 426 |  |  | $ | (1 | )
Product |  |  | 64 |  |  |  | 9 |
|  | $ | 490 |  |  | $ | 8 |
| (b) | Geographic Information
|  | Years Ended September 30, |  |  |  |  |
|  | 2014 |  |  | 2013 |  |  |  |  |
Sales to External Customers: |  |  |  |  |  |  |  |
North America |  | $ | 22,184 |  |  | $ | 19,635 |
Pacific Rim |  |  | 740 |  |  |  | 1,019 |
Europe |  |  | 1,086 |  |  |  | 1,111 |
Other |  |  | 574 |  |  |  | 303 |
|  | $ | 24,584 |  |  | $ | 22,068 |
Long-lived Assets: |  |  |  |  |  |  |  |
North America |  | $ | 17,119 |  |  | $ | 18,364 |
|  | $ | 17,119 |  |  | $ | 18,364 |
| (c) | Major Customers
In fiscal 2014 our preclinical services group significantly expanded its presence at two important existing customers. In fiscal 2014, Arrowhead accounted for approximately 12.1% of total sales and 18.5% of total trade accounts receivable at September 30, 2014. In fiscal 2013, Arrowhead accounted for approximately 0.4% of total sales and 4.6% of total trade accounts receivable at September 30, 2013. In fiscal 2014, Principia Biopharma accounted for approximately 8.7% of total sales and 8.4% of total trade accounts receivable at September 30, 2014. In fiscal 2013, Principia Biopharma accounted for approximately 0.4% of total sales and7.1% of total trade accounts receivable at September 30, 2013. Both Arrowhead and Principia Biopharma are included in our contract research services segment. In fiscal 2014, Boehringer Ingelheim remained an important customer, accounting for approximately 5.9% of total sales and 2.5% of total trade accounts receivable at September 30, 2014. In fiscal 2013, Boehringer Ingelheim accounted for approximately 6.0% of total sales and 2.6% of total trade accounts receivable at September 30, 2013. Pfizer, Inc. also remains an important large client, accounting for approximately 1.7% and 4.9% of our total revenues in fiscal 2014 and 2013, respectively. Pfizer, Inc. accounted for 1.5% and 3.3% of total trade accounts receivable at September 30, 2014 and 2013, respectively. Both Boehringer Ingelheim and Pfizer are included in our contract research services segment.

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration